Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Hypertension
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Hypertension
    TopAbstracts in Hypertension 11/26/2008 - (DGNews)
    Potassium Loss Caused by Thiazides May Explain Higher Risk of Adult Diabetes - (DGNews)
    High Blood Pressure in Doctor's Office May Not Predict Heart Risks - (DGNews)
    TopAbstracts in Hypertension 11/19/2008 - (DGNews)
    Aliskiren Helps Elderly Patients Achieves Blood Pressure Control: Presented at AHA - (DGDispatch)

    News archive

     Recent webcasts/CME - Hypertension
    • Minimizing Cardiovascular Risk in Patients With Dyslipidemia
    • Beta-Blockers in Hypertension - The Con Discussion
      Vaccination: A New Approach to RAAS Inhibition?
      Beta-Blockers in Hypertension - The Pro Discussion
      Which Anti-RAAS Shall We Use?

      Webcasts/CME archive

       Recent cases - Hypertension
        Aortic Dissection Type I in a Weightlifter with Hypertension: A Case Report
        Transient Left Ventricular Apical Ballooning and Exercise Induced Hypertension During Treadmill Exercise Testing: Is There a Common Hypersympathetic Mechanism?
        Dilation of Renal Artery Stenosis after Administration of Losartan
        Angioedema of the Tongue
        Primary Aldosteronism Caused by a Unilateral Adrenal Adenoma Accompanied by Autonomous Cortisol Secretion

        Cases archive
          




        my personal edition > hypertension > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Controlled Onset Extended Release Verapamil At Bedtime May Better Control Morning Blood Pressure, Heart Rate

        A DGReview of :"Preventing increases in early-morning blood pressure, heart rate, and the rate-pressure product with controlled onset extended release verapamil at bedtime versus enalapril, losartan, and placebo on arising."
        American Heart Journal

        10/09/2002
        By Andrew A. Skolnick


        The administration of controlled onset extended release verapamil at bedtime may control morning blood pressure, heart rate and heart rate systolic blood pressure better than conventional, antihypertensive agents taken in the morning.

        Therapeutic agents for the treatment of hypertension may differ in their efficacy during the early-morning period, when the risk of cardiovascular events is highest.

        William B. White, MD, and colleagues at the University of Connecticut School of Medicine, in Farmington, Connecticut, United States, compared the haemodynamic effects of a chronotherapeutic delivery system of verapamil taken at bedtime, versus the conventional morning administration of enalapril or losartan.

        The study involved 357 men and women with an untreated sitting diastolic blood pressure of 95 to 114 mm Hg and ambulatory daytime diastolic blood pressure greater than or equal to 85 mm Hg.

        The patients were randomized to receive either COER-verapamil hydrochloride each evening (240 mg titrated to 360 mg), enalapril each morning (10 mg titrated to 20 mg), losartan each morning (50 mg titrated to 100 mg), or placebo. Early morning assessments of blood pressure, heart rate, and the heart rate systolic blood pressure product were performed by use of 24-hour ambulatory recordings after four weeks of low dose and eight weeks of high dose therapy.

        Results were similar at weeks four and eight for all treatment groups, except that the magnitude of change was greater at week eight. After eight weeks of treatment, reductions in early morning blood pressure by COER-verapamil were significantly greater (-15/-10 mm Hg) than enalapril (-9/-7 mm Hg) and losartan (-8/-5 mm Hg), the researchers reported.

        COER-verapamil also led to greater reductions in morning heart rate, the rate-pressure product, and the rate-of-rise of blood pressure compared with the other two active treatment groups. Reductions in mean 24-hour blood pressure were greater in patients treated with COER-verapamil compared with those taking placebo or losartan, and was similar to reductions in patients treated with enalapril.

        "Bedtime administration of an agent designed to parallel the circadian rhythm of blood pressure and heart rate led to significantly greater early morning haemodynamic effects compared with other conventional once-daily antihypertensive agents dosed in the morning," the researchers concluded.
        Am Heart J 2002; 144: 657-665. "Preventing increases in early-morning blood pressure, heart rate, and the rate-pressure product with controlled onset extended release verapamil at bedtime versus enalapril, losartan, and placebo on arising."

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send